Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings
Carregando...
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUNPEC-EDITORA
Autores
FRANCO, J. F.
SOARES, D. C.
TORRES, L. C.
Citação
GENETICS AND MOLECULAR RESEARCH, v.15, n.1, article ID UNSP 15017850, 7p, 2016
Resumo
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive multisystem lysosomal storage disorder, which is characterized by the deficiency of the enzyme arylsulfatase B encoded by the ARSB gene. Treatment of this disease with enzyme-replacement therapy (ERT) improves the clinical status of and generates hope for MPS VI patients. However, only few reports on patients with MPS VI treated before 5 years of age have been published. Thus, the objective of this study was to compare the clinical parameters of two sisters affected by MPS VI who started ERT at different ages (9 years and 1 year 5 months, respectively) and to determine the most relevant clinical impacts of early treatment after 85 months of evaluation. The treatment was well tolerated by both siblings. ERT in the younger sibling resulted in increased growth, an improved 6-minute walk test, less coarse face, slower progression of cardiac valve disease, and the absence of compressive myelopathy compared to that in her older sister. On the other hand, the older sibling had typical MPS VI phenotypic features before the commencement of ERT. Corneal clouding, clawed hands, and progressive skeletal changes were observed in both siblings despite the treatment. Both siblings displayed reduced frequencies of upper respiratory infections and apnea indices. This study emphasizes that early diagnosis and treatment of MPS VI are critical for a better disease outcome and to enhance the quality of life for these patients.
Palavras-chave
Enzyme-replacement therapy, Galsulfase, Glycosaminoglycan, Mucopolysaccharidosis, Arylsulfatase B, N-acetylgalactosamine-4-sulfatase
Referências
- LITJENS T, 1989, HUM GENET, V82, P67, DOI 10.1007/BF00288275
- Herskhovitz E, 1999, J INHERIT METAB DIS, V22, P50, DOI 10.1023/A:1005447232027
- Harmatz P, 2006, J PEDIATR-US, V148, P533, DOI 10.1016/j.jpeds.2005.12.014
- Guimaraes MDM, 2010, ORAL HLTH PREV DENT, V8, P139
- Auclair D, 2003, MOL GENET METAB, V78, P163, DOI 10.1016/S1096-7192(03)00007-6
- Petry MFG, 2005, J INHERIT METAB DIS, V28, P1027, DOI 10.1007/s10545-005-0020-2
- Horovitz DDG, 2013, MOL GENET METAB, V109, P62, DOI 10.1016/j.ymgme.2013.02.014
- Swiedler SJ, 2005, AM J MED GENET A, V134A, P144, DOI 10.1002/ajmg.a.30579
- Furujo M, 2011, MOL GENET METAB, V104, P597, DOI 10.1016/j.ymgme.2011.08.029
- Giugliani R, 2007, PEDIATRICS, V120, P405, DOI 10.1542/peds.2006-2184
- Harmatz P, 2008, MOL GENET METAB, V94, P469, DOI 10.1016/j.ymgme.2008.04.001
- Garrido E, 2008, MOL GENET METAB, V94, P305, DOI 10.1016/j.ymgme.2008.02.012
- Muenzer J, 2014, MOL GENET METAB, V111, P63, DOI 10.1016/j.ymgme.2013.11.015
- McGill JJ, 2010, CLIN GENET, V77, P492, DOI 10.1111/j.1399-0004.2009.01324.x
- Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
- Leal GN, 2014, CARDIOL YOUNG, V24, P229, DOI 10.1017/S1047951113000152
- Harmatz P, 2004, J PEDIATR-US, V144, P574, DOI 10.1016/j.jpeds.2004.03.018